Sensorion (ALSEN) Stock Overview

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1G; GJB2-GT, a gene therapy development program aims to restore hearing in people living with hearing loss due to mutations in the GJB2 gene; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.